Boscia Bb Spf 27 Pa
Titanium Dioxide
Boscia Llc
Human Otc Drug
NDC 76151-210Boscia Bb Spf 27 Pa also known as Titanium Dioxide is a human otc drug labeled by 'Boscia Llc'. National Drug Code (NDC) number for Boscia Bb Spf 27 Pa is 76151-210. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Boscia Bb Spf 27 Pa drug includes Titanium Dioxide - 6.4 g/100g . The currest status of Boscia Bb Spf 27 Pa drug is Active.
Drug Information:
| Drug NDC: | 76151-210 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Boscia Bb Spf 27 Pa |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Titanium Dioxide |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Boscia Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Cream |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | TITANIUM DIOXIDE - 6.4 g/100g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 11 May, 2011 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 19 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part352 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2024 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| UNII: | |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 76151-210-01 | 50 g in 1 BOTTLE (76151-210-01) | 19 Dec, 2017 | N/A | No |
| 76151-210-95 | 10 g in 1 BOTTLE (76151-210-95) | 19 Dec, 2017 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Use helps prevent sunburn. higher spf gives more sunburn protection.
Product Elements:
Boscia bb spf 27 pa titanium dioxide water cyclomethicone 5 glycerin sodium pyrrolidone carboxylate glycereth-26 dimethicone dipropylene glycol arbutin panthenol phenyl trimethicone hyaluronate sodium butylene glycol stearic acid caprylyl glycol triethoxycaprylylsilane aluminum oxide mica citric acid monohydrate sodium chloride sodium anisate ferrosoferric oxide ferric oxide red ferric oxide yellow titanium dioxide titanium dioxide
Warnings:
Warnings for external use only. use as directed.
When Using:
Avoid direct contact with eyes. if contact occurs, rinse gently with water.
Dosage and Administration:
Directions apply in am to cleansed and toned face as last skincare step. reapply as needed or after towel drying, swimming or perspiring.
Stop Use:
Discontinue use and consult a physician immediately if any adverse reaction occurs.
Description:
This b.b. cream creates a lustrous, flawless finish as it hydrates, firms and soothes the skin. helps diminish the appearance of pores, fine lines and uneven skintone while providing long-wearing, natural coveage that conceals imperfections. abyssine, a naturally-derived survival molecule, shields and soothes skin while hydroxyprolisilane promotes skin elasticity and reduces the appearance of fine lines. beta-glucon provides essential moisture and protects against environmental damage. preservative-free. dermatologist tested. alcohol-free, ph balanced, 100% artificial fragrance and color free. no animal testing and no animal ingredients. www.boscia.net b210-01 distributed by boscia, llc. irvine, ca 92614 made in u.s.a. b11-1
Package Label Principal Display Panel:
Boscia b.b. cream spf 27 pa++
This b.b. cream creates a lustrous, flawless finish as it hydrates, firms and soothes the skin. helps diminish the appearance of pores, fine lines and uneven skintone while providing long-wearing, natural coveage that conceals imperfections. abyssine, a naturally-derived survival molecule, shields and soothes skin while hydroxyprolisilane promotes skin elasticity and reduces the appearance of fine lines. beta-glucon provides essential moisture and protects against environmental damage.
Preservative-free. dermatologist tested. alcohol-free, ph balanced, 100% artificial fragrance and color free. no animal testing and no animal ingredients. www.boscia.net b210-01 distributed by boscia, llc. irvine, ca 92614 made in u.s.a. b11-1
Bb cream a
Bb cream b
Bb cream c